{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:41:43Z","timestamp":1794649303692,"version":"4.9.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Bimagrumab is a monoclonal antibody that targets activin type II receptors, blocks myostatin and related proteins: it promotes muscle growth and prevents muscle loss, while causing weight loss. It has been effective in sporadic inclusion body myositis with promising results, a disease that had no previous effective therapy. It has also been studied in sarcopenia, leading to improved muscle mass and reduced fat mass. It has been very effective in obese patients with type 2 diabetes, leading to reduced fat mass, increased lean body mass, and improved insulin sensitivity. Subcutaneous administration is now as effective as intravenous dosing. It has improved muscle mass in patients with sarcopenia and posthip fracture recovery, while only showing minimal improvements in mobility and strength. It has recently been used in combination with semaglutide, a glucagon-like peptide-1 receptor agonist administered weekly as a subcutaneous injection for weight loss. Semaglutide reduces appetite, slows gastric emptying, and improves glucose regulation. As much as 40% of weight loss may come from lean body mass, primarily skeletal muscle, raising concerns about sarcopenia. Bimagrumab is a promising solution to counter the muscle-wasting effects of semaglutide. We review the development of bimagrumab, its mechanism of action, clinical trial results, and the safety profile. We compare the efficacy of the combination of bimagrumab and semaglutide to a dual incretin glucagon-like peptide-1 receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) drug. Finally, we will show the superiority of bimagrumab to other myostatin inhibitors.<\/jats:p>","DOI":"10.1097\/crd.0000000000001113","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T01:00:13Z","timestamp":1763427613000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Bimagrumab: Novel Medical Therapy for Inclusion Body Myositis, Sarcopenia, and Medication-Induced Lean Body Mass Loss"],"prefix":"10.1097","author":[{"given":"Michael","family":"Kaiser","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioia","family":"Turitto","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"R2-20251118","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1515\/jbcpp-2024-0065","article-title":"Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity.","volume":"35","author":"Kaur","year":"2024","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"R3-20251118","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Bimagrumab for sporadic inclusion body myositis.","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"R4-20251118","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40520-024-02825-4","article-title":"Effect of bimagrumab on body composition: a systematic review and meta-analysis.","volume":"36","author":"Kanbay","year":"2024","journal-title":"Aging Clin Exp Res"},{"key":"R5-20251118","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s40520-024-02915-3","article-title":"Bimagrumab and sarcopenia.","volume":"37","author":"Can","year":"2025","journal-title":"Aging Clin Exp Res"},{"key":"R6-20251118","doi-asserted-by":"crossref","first-page":"e13718","DOI":"10.1002\/jcsm.13718","article-title":"The effect of anti-activin receptor type IIA and type IIB antibody on muscle, bone and blood in healthy and osteosarcopenic mice.","volume":"16","author":"Bromer","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R7-20251118","first-page":"e1592","article-title":"RESILIENT trial: bimagrumab in sIBM.","volume":"92","author":"Hanna","year":"2019","journal-title":"Neurology"},{"key":"R8-20251118","first-page":"1647","article-title":"Sarcopenia trial: bimagrumab efficacy in older adults.","volume":"75","author":"Rooks","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R9-20251118","first-page":"1842","article-title":"Bimagrumab in sarcopenia and post-hip fracture recovery.","volume":"69","author":"Rooks","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"R10-20251118","first-page":"1796","article-title":"Bimagrumab in obese adults with type 2 diabetes.","volume":"23","author":"Heymsfield","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R11-20251118","first-page":"2045","article-title":"Subcutaneous bimagrumab dosing in healthy older adults.","volume":"13","author":"Polkey","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R12-20251118","first-page":"1132","article-title":"BELIEVE Phase 2b trial: bimagrumab and semaglutide in obese adults.","volume":"46","author":"Hanna","year":"2023","journal-title":"Diabetes Care"},{"key":"R13-20251118","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","volume":"49","author":"Melson","year":"2025","journal-title":"Int J Obes"},{"key":"R14-20251118","doi-asserted-by":"crossref","first-page":"101880","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol Metab"},{"key":"R15-20251118","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40262-022-01189-0","article-title":"Pharmacokinetics and pharmacodynamics of bimagrumab (BYM338).","volume":"62","author":"Petricoul","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R16-20251118","doi-asserted-by":"crossref","first-page":"156057","DOI":"10.1016\/j.metabol.2024.156057","article-title":"The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.","volume":"161","author":"Stefanakis","year":"2024","journal-title":"Metabolism"},{"key":"R17-20251118","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11154-025-09967-4","article-title":"New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?","volume":"26","author":"Ryan","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"key":"R18-20251118","first-page":"368","article-title":"Safety profile of bimagrumab: RESILIENT trial extension.","volume":"62","author":"Hanna","year":"2020","journal-title":"Muscle Nerve"},{"key":"R19-20251118","first-page":"789","article-title":"Phase 2 COURAGE trial: semaglutide with trevogrumab and garetosmab in obesity.","volume":"404","author":"Wharton","year":"2024","journal-title":"Lancet"},{"key":"R20-20251118","doi-asserted-by":"crossref","first-page":"e005176","DOI":"10.1136\/rmdopen-2024-005176","article-title":"Efficacy and safety of pharmacological treatments in inclusion body myositis: a systematic review.","volume":"11","author":"Santos","year":"2025","journal-title":"RMD Open"},{"key":"R21-20251118","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"STEP 1 trial: semaglutide for weight loss.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"R22-20251118","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"R23-20251118","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"R24-20251118","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with obesity: the SURMOUNT-3 trial.","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"R25-20251118","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 trial.","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"R26-20251118","first-page":"234","article-title":"Phase 2 COURAGE trial outcomes: semaglutide with myostatin inhibitors.","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"R27-20251118","first-page":"e2793","article-title":"Resistance exercise and semaglutide: muscle preservation.","volume":"107","author":"Houtkooper","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-20251118","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clnu.2025.06.007","article-title":"Therapeutic advances in sarcopenia management: from traditional interventions to personalized medicine.","volume":"51","author":"Liu","year":"2025","journal-title":"Clin Nutr"},{"key":"R29-20251118","doi-asserted-by":"crossref","first-page":"170939","DOI":"10.1016\/j.peptides.2023.170939","article-title":"An update on peptide-based therapies for type 2 diabetes and obesity.","volume":"161","author":"Bailey","year":"2023","journal-title":"Peptides"},{"key":"R30-20251118","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/jamainternmed.2023.8526","article-title":"Approach to obesity treatment in primary care: a review.","volume":"184","author":"Yanovski","year":"2024","journal-title":"JAMA Intern Med"},{"key":"R31-20251118","first-page":"351","article-title":"Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary?","volume":"28","author":"Chavez","year":"2025","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R32-20251118","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/diseases13050129","article-title":"Current and emerging parenteral and peroral medications for weight loss: a narrative review.","volume":"13","author":"Al Lawati","year":"2025","journal-title":"Diseases"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T01:00:18Z","timestamp":1763427618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001113","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}